Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96PN6

UPID:
ADCYA_HUMAN

ALTERNATIVE NAMES:
AH-related protein; Adenylate cyclase homolog; Germ cell soluble adenylyl cyclase; Testicular soluble adenylyl cyclase

ALTERNATIVE UPACC:
Q96PN6; B4DZF0; F5GWS5; O95558; Q5R329; Q5R330; Q8WXV4; Q9NNX0

BACKGROUND:
The Adenylate cyclase type 10 enzyme, known for its alternative names such as Germ cell soluble adenylyl cyclase, is a key player in the production of cAMP, a signaling molecule vital for various cellular processes. Its role extends to sensing changes in cellular bicarbonate and CO2 levels, and it is critically involved in the maturation of sperm in the epididymis, as well as in the regulation of ciliary beat.

THERAPEUTIC SIGNIFICANCE:
Given its association with Hypercalciuria absorptive 2, a disorder characterized by gastrointestinal hyperabsorption of calcium, Adenylate cyclase type 10 presents a promising target for therapeutic intervention. Exploring the mechanisms by which this protein influences disease pathways could lead to novel treatments for calcium oxalate nephrolithiasis and related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.